The pharmacology of azabicyclane, a new analgesic agent.
D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000996:Antitussive Agents / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D003250:Constriction; D004064:Digestive System / Q000187:drug effects; D004357:Drug Synergism; D004361:Drug Tolerance; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008614:Meperidine / Q000494:pharmacology / Q000633:toxicity; D008722:Methods; D051379:Mice; D009020:Morphine / Q000494:pharmacology; D009269:Nalorphine / Q000037:antagonists & inhibitors; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology* / Q000633:toxicity; D011680:Pupil / Q000187:drug effects; D051381:Rats; D012119:Respiration / Q000187:drug effects; D019966:Substance-Related Disorders; D013874:Thiopental
D000700:Analgesics; D000996:Antitussive Agents; D010880:Piperidines; D009020:Morphine; D008614:Meperidine; D013874:Thiopental; D009269:Nalorphine